Shares of Monte Rosa Therapeutics (GLUE) have gained 54.5% over the past four weeks to close the last trading session at $8.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 100.5%.The average comprises six short-term price targets ranging from a low of $15 to a high of $20, with a standard deviation of $2.45. While the lowest estimate indic ...